IMVT Immunovant, Inc.
Immunovant, Inc. (IMVT) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 9% planned / 91% discretionary
Largest single sale: $7.1M.
Where they traded
Last open-market purchase: December 12, 2025 , by Roivant Sciences Ltd. .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Pande Atul | Director | Sell 10b5-1 | 1,500 | $43.27 | $64.9K | 116,731 −1.3% of holding | |
| Gloria Melanie | Chief Operating Officer | Sell | 3,056 | $44.16 | $135.0K | 219,301 −1.4% of holding | |
| Pande Atul | Director | Sell 10b5-1 | 1,500 | $39.80 | $59.7K | 116,731 −1.3% of holding | |
| Girao Tiago | Chief Financial Officer | Sell | 6,798 | $38.69 | $263.0K | 240,798 −2.7% of holding | |
| Stout Jay S | Chief Technology Officer | Sell | 2,857 | $38.69 | $110.5K | 205,341 −1.4% of holding | |
| Stout Jay S 4 fills | Chief Technology Officer | Sell | 3,487 | $39.55 | $137.9K | 209,779 −1.6% of holding | |
| Gloria Melanie 2 fills | Chief Operating Officer | Sell | 2,036 | $39.55 | $80.5K | 222,463 −0.9% of holding | |
| Van Tuyl Christopher 2 fills | Chief Legal Officer | Sell | 1,206 | $39.55 | $47.7K | 179,454 −0.7% of holding | |
| Venker Eric | Chief Executive Officer | Sell | 3,092 | $38.48 | $119.0K | 254,280 −1.2% of holding | |
| Stout Jay S 2 fills | Chief Technology Officer | Sell | 40,000 | $38.31 | $1.5M | 218,408 −15.5% of holding | |
| Van Tuyl Christopher 2 fills | Chief Legal Officer | Sell | 17,824 | $38.31 | $682.9K | 183,439 −8.9% of holding | |
| Gloria Melanie 2 fills | Chief Operating Officer | Sell | 17,714 | $38.31 | $678.6K | 227,359 −7.2% of holding | |
| Girao Tiago | Chief Financial Officer | Sell | 10,000 | $38.46 | $384.6K | 247,596 −3.9% of holding | |
| Pande Atul | Director | Sell 10b5-1 | 1,500 | $38.01 | $57.0K | 116,731 −1.3% of holding | |
| Van Tuyl Christopher | Chief Legal Officer | Sell | 2,634 | $35.39 | $93.2K | 180,597 −1.4% of holding | |
| Pande Atul | Director | Sell 10b5-1 | 1,500 | $34.02 | $51.0K | 116,731 −1.3% of holding | |
| Fromkin Andrew J. 2 fills | Director | Sell | 221,951 | $33.51 | $7.4M | 284,850 −43.8% of holding | |
| Pande Atul | Director | Sell 10b5-1 | 6,000 | $32.00 | $192.0K | 116,731 −4.9% of holding | |
| Gloria Melanie 3 fills | Chief Operating Officer | Sell | 3,115 | $32.45 | $101.1K | 244,973 −1.3% of holding | |
| Susman Robert Graham | Director | Sell 10b5-1 | 2,502 | $27.17 | $68.0K | 36,394 −6.4% of holding | |
| Girao Tiago | Chief Financial Officer | Sell | 25,760 | $29.62 | $763.0K | 247,596 −9.4% of holding | |
| Stout Jay S | Chief Technology Officer | Sell | 2,754 | $29.62 | $81.6K | 251,685 −1.1% of holding | |
| Stout Jay S 2 fills | Chief Technology Officer | Sell | 10,132 | $24.83 | $251.6K | 255,957 −3.8% of holding | |
| Gloria Melanie | Chief Operating Officer | Sell | 8,722 | $24.83 | $216.6K | 245,222 −3.4% of holding | |
| Van Tuyl Christopher | Chief Legal Officer | Sell | 5,165 | $24.83 | $128.2K | 183,231 −2.7% of holding | |
| Venker Eric 2 fills | Chief Executive Officer | Sell | 14,229 | $24.10 | $342.9K | 20,970 −40.4% of holding | |
| Van Tuyl Christopher | Chief Legal Officer | Sell | 2,877 | $24.97 | $71.8K | 147,053 −1.9% of holding | |
| Gloria Melanie 3 fills | Chief Operating Officer | Sell | 3,238 | $27.85 | $90.2K | 172,074 −1.8% of holding | |
| Stout Jay S | Chief Technology Officer | Sell | 1,977 | $26.03 | $51.5K | 197,634 −1% of holding | |
| Stout Jay S 2 fills | Chief Technology Officer | Sell | 1,203 | $26.53 | $31.9K | 199,666 −0.6% of holding | |
| Van Tuyl Christopher 2 fills | Chief Legal Officer | Sell | 10,813 | $26.91 | $290.9K | 152,214 −6.6% of holding | |
| Roivant Sciences Ltd. | Director | Buy | 16,666,666 | $21.00 | $350.0M | 113,317,007 | |
| Fromkin Andrew J. 2 fills | Director | Sell 10b5-1 | 22,249 | $23.25 | $517.2K | 88,750 −20% of holding | |
| Hughes Douglas J. 2 fills | Director | Sell 10b5-1 | 15,000 | $23.24 | $348.7K | 122,682 −10.9% of holding | |
| Gloria Melanie 2 fills | Chief Operating Officer | Sell | 12,626 | $23.62 | $298.2K | 175,886 −6.7% of holding | |
| Geffner Michael | Chief Medical Officer | Sell | 2,595 | $19.03 | $49.4K | 217,958 −1.2% of holding | |
| Stout Jay S | Chief Technology Officer | Sell | 2,520 | $19.03 | $48.0K | 200,814 −1.2% of holding | |
| Stout Jay S | Chief Technology Officer | Sell | 1,585 | $16.30 | $25.8K | 203,334 −0.8% of holding | |
| Geffner Michael | Chief Medical Officer | Sell | 1,272 | $16.30 | $20.7K | 220,553 −0.6% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.